6 results about "Hydroxylamine compound" patented technology

The present application relates to a kind of five-ring thiazole indole ketone piperazine amide derivatives and purposes thereof.The derivatives take ethyl cyanoacetate as starting material, generate hydroxylamine compound (A) under the action of sodium nitrite and phosphoric acid;Obtain 2-amino ethyl cyanoacetate (B) by reduction, in turn with acetic anhydride, lawson reagent is reacted, and 5-amino-4-carboxylate thiazole compound (D) is obtained;After bromination by NBS, under the catalysis of phosphorus oxychloride, react with tetrahydropyridine indole ketone, generate 2-bromo-6,7-dihydrothiazolo [5'',4'':4',5'] pyrimido [1',2':1,2] pyrindo [3,4-b] indole-4 (12H) -ketone (F), again under alkaline condition, first with Boc piperazine, then by Boc treatment and obtain compound (H);Finally, react with acyl chloride, and 28 different substitution structures of five-ring thiazole indole ketone piperazine amide compound (I1-I28) are synthesized.The 28 compounds are tested on three kinds of cancer cells, and the results show that: 28 compounds have significant inhibitory activity on Hela cervical cancer cells, HT-29 human colon cancer cells and HGC-27 human gastric cancer cells.

This application relates to the field of polypropylene masterbatch processing technology, and more specifically, to a medical-grade polypropylene masterbatch resistant to gamma-ray radiation color change and its preparation method. It is prepared from the following raw materials in parts by weight: 40-80 parts polypropylene carrier resin, 5-10 parts radiation-resistant composite stabilizer, 3-5 parts dispersant, 1-2 parts processing aid, and 0-5 parts pigment. The radiation-resistant composite stabilizer is composed of a non-phenolic antioxidant, an N-alkoxy hindered amine light stabilizer, and a crystallization regulator. The non-phenolic antioxidant is a benzofuranone compound and / or a hydroxylamine compound. The crystallization regulator is at least one of a sorbitol nucleating agent, liquid paraffin, and low molecular weight polyolefin wax. This formulation can improve the color stability and mechanical property retention of medical polypropylene products, prevent embrittlement during storage, and meet the stringent requirements of medical devices for high transparency, high toughness, and long-term storage stability.

This invention discloses a method for preparing hydroxylamine compounds by reducing nitroketone compounds without a metal catalyst. This method uses benzylsilane as a hydrogen source and toluene as a solvent, requiring no additional metal catalyst. The reduction product is obtained by stirring the reaction at 70–80°C under inert gas protection and a closed system. This invention employs a metal catalyst-free system for the reduction of nitroketone compounds, offering advantages such as low cost, mild reaction conditions, and high selectivity. It avoids the use of special equipment such as hydrogen and autoclaves, as well as excessive sodium borohydride reducing agents.

This invention relates to a pentacyclic thiazole indole sulfonyl piperazine derivative and its uses. The synthesis of this derivative begins with ethyl cyanoacetate as the starting material, which, under the synergistic effect of sodium nitrite and phosphoric acid, generates a hydroxylamine compound (1); after reduction, ethyl 2-aminocyanoacetate (2) is obtained, which is then reacted sequentially with acetic anhydride and Lawson's reagent to obtain a 5-amino-4-carboxylate thiazole compound (4); after NBS bromination, it reacts with tetrahydropyridine indole ketone under the catalysis of phosphorus oxychloride to generate 2-bromo-6,7-dihydrothiazo[5'',4'':4',5']pyrimidin[ [1',2':1,2]pyrido[3,4-b]indole-4(12H)-one (6) was first reacted with Boc piperazine under alkaline conditions, and then deprotected by Boc to obtain compound (8); finally, it was reacted with sulfonyl chloride to synthesize 28 pentacyclic thiazole indole one sulfonyl piperazine compounds 9a-9ab. The inhibitory activity of these 28 compounds against HeLa cervical cancer cells, HT-29 human colon cancer cells and HGC-27 human gastric cancer cells was investigated.

The application provides an On-DNA-gamma-hydroxylamine compound and a preparation method thereof, and belongs to the field of gene coding compound library construction. The On-DNA-gamma-hydroxylamine compound is a compound shown in formula I. The method for synthesizing the On-DNA-gamma-hydroxylamine compound has small DNA damage, good universality, simple operation and mild conditions. The On-DNA-gamma-hydroxylamine compound has high yield, and the DNA integrity in the product is good. The application enriches the chemical reaction type for synthesizing the coding compound library on DNA, establishes a method for constructing a gene coding compound library with a new gamma-hydroxylamine skeleton, and has a very good application prospect in lead drug development.